ConductScience.org, home
Papers
API referenceFor AI assistants

Paper3933817

Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.

Bocian RC and 3 others. Cancer Immunol Immunother, 1985. Cited by 11 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. Papers, record 3933817. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3933817

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
1985
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.44
iCite
Revised in PubMed
2024-04-26
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bocian RCR C
2Dray SS
3Ben-Efraim SS
4Mokyr MBM B

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cytotoxicity, ImmunologicMajor topic
Immunity, CellularMajor topic
MelphalanMajor topic
Neoplasms, ExperimentalMajor topic
Animals
Cell Division
Mice
Mitomycin
Mitomycins
Neoplasm Metastasis
Spleen

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-30088NCI NIH HHSUnited StatesR01CA030088PubMed and NIHNIH RePORTER
CA-35761NCI NIH HHSUnited StatesR01CA035761PubMed and NIHNIH RePORTER

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17,432,433Dose-response effect of adjuvant chemotherapy in breast cancer.N Engl J Med1981https://conductscience.org/library/papers/7432433PubMed
26,609,993A helper factor needed for the generation of mouse cytolytic T lymphocytes is made by tumor cell lines, cloned T cells, and spleen cells exposed to a variety of stimuli.J Immunol1984https://conductscience.org/library/papers/6609993PubMed
34,198,384Haptenic activity of L-phenylalanine mustard.Cancer Res1973https://conductscience.org/library/papers/4198384PubMed
4157,800Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.Cancer Res1979https://conductscience.org/library/papers/157800PubMed
56,965,292Origin and function of suppressor macrophages in myeloma.J Immunol1980https://conductscience.org/library/papers/6965292PubMed
66,409,398Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo.Cancer Res1983https://conductscience.org/library/papers/6409398PubMed
75,369,682Induced immunologic response to tumors.Cancer Res1969https://conductscience.org/library/papers/5369682PubMed
8304,590Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time.Recent Results Cancer Res1977https://conductscience.org/library/papers/304590PubMed
9659,903In vitro induction of cell-mediated immunity to murine leukemia cells. IV. Amplification of the generation of cytotoxic lymphocytes by enzymatically and chemically modified stimulator leukemic cells.J Immunol Methods1978https://conductscience.org/library/papers/659903PubMed
10286,122
Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
J Natl Cancer Inst1979https://conductscience.org/library/papers/286122PubMed
116,446,379Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.Cancer Res1980https://conductscience.org/library/papers/6446379PubMed
126,767,871Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells.J Natl Cancer Inst1980https://conductscience.org/library/papers/6767871PubMed
13701,801Myeloma-induced immunosuppression: a multistep mechanism.J Immunol1978https://conductscience.org/library/papers/701801PubMed
14304,748Human cell lines that elaborate colon-stimulating activity for the marrow cells of man and other species.Blood1978https://conductscience.org/library/papers/304748PubMed
153,922,904Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.Int J Immunopharmacol1985https://conductscience.org/library/papers/3922904PubMed
1675,062In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.Cancer Res1978https://conductscience.org/library/papers/75062PubMed
176,289,661Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer.Am J Med1982https://conductscience.org/library/papers/6289661PubMed
184,818,273Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.Int J Cancer1974https://conductscience.org/library/papers/4818273PubMed
196,353,885Antigenic tumor cell variants obtained with mutagens.Adv Cancer Res1983https://conductscience.org/library/papers/6353885PubMed
207,016,310Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.Cancer Res1981https://conductscience.org/library/papers/7016310PubMed

See all 38 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
2,787,695Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2787695PubMed
2,657,252Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.Med Oncol Tumor Pharmacother1989https://conductscience.org/library/papers/2657252PubMed
2,337,902Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.Cancer Immunol Immunother1990https://conductscience.org/library/papers/2337902PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3933817

GET https://conductscience.org/api/papers/v1/3933817/references?page=2

API referenceFor AI assistants